Motley Fool Wealth Management LLC Sells 37,858 Shares of Inari Medical, Inc. (NASDAQ:NARI)

Motley Fool Wealth Management LLC lessened its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 17.8% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 174,360 shares of the company’s stock after selling 37,858 shares during the quarter. Motley Fool Wealth Management LLC’s holdings in Inari Medical were worth $9,686,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. grew its position in Inari Medical by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 5,628,875 shares of the company’s stock worth $287,354,000 after acquiring an additional 30,702 shares in the last quarter. Jennison Associates LLC increased its stake in shares of Inari Medical by 11.8% in the 4th quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after acquiring an additional 186,617 shares in the last quarter. Vestal Point Capital LP boosted its holdings in Inari Medical by 342.9% in the third quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after acquiring an additional 1,200,000 shares in the last quarter. American Century Companies Inc. increased its position in shares of Inari Medical by 9.1% during the fourth quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock valued at $54,546,000 after acquiring an additional 89,108 shares in the last quarter. Finally, Bamco Inc. NY raised its position in Inari Medical by 29.5% in the 3rd quarter. Bamco Inc. NY now owns 1,006,129 shares of the company’s stock worth $41,493,000 after buying an additional 228,977 shares during the last quarter. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analysts Set New Price Targets

NARI has been the topic of several analyst reports. Piper Sandler lifted their target price on Inari Medical from $52.00 to $80.00 and gave the company a “neutral” rating in a research report on Tuesday, January 7th. BTIG Research reissued a “neutral” rating on shares of Inari Medical in a research report on Wednesday, January 8th. Canaccord Genuity Group restated a “hold” rating and set a $80.00 price objective (up from $74.00) on shares of Inari Medical in a report on Tuesday, January 7th. Wells Fargo & Company restated an “equal weight” rating and set a $80.00 price objective (up from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Finally, Robert W. Baird reissued a “neutral” rating and set a $80.00 target price (down previously from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Inari Medical presently has an average rating of “Hold” and an average price target of $68.00.

Insider Transactions at Inari Medical

In other Inari Medical news, Director William Hoffman sold 200,000 shares of the company’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the completion of the sale, the director now directly owns 238,987 shares in the company, valued at $14,451,543.89. This represents a 45.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders own 10.60% of the company’s stock.

Inari Medical Stock Performance

Shares of NARI opened at $79.97 on Wednesday. Inari Medical, Inc. has a 12-month low of $36.73 and a 12-month high of $79.99. The company has a 50-day moving average of $79.84 and a two-hundred day moving average of $60.81. The stock has a market cap of $4.68 billion, a P/E ratio of -59.24 and a beta of 1.02.

Inari Medical Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.